MIRA Pharmaceuticals, Inc. Proceeds from Long-term Lines of Credit
MIRA Pharmaceuticals, Inc. (MIRA) reported Proceeds from Long-term Lines of Credit of $2.15 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2025-03-28
- MIRA Pharmaceuticals, Inc. proceeds from long-term lines of credit for fiscal 2023 was $2.15M.
| Period end | Proceeds from Long-term Lines of Credit 12 month |
|---|---|
| 2023-12-31 | $2.15M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |